Page 200 - Aet News Today

Posterity Health recently raised $7.5 million in an oversubscribed funding round. The startup's digital male fertility platform offers a combination of virtual visits, at-home diagnostics and in-person consultations to assess and improve patients' fertility status.

Eli Lilly’s accelerated approval application for its Alzheimer’s disease drug has fallen short. The company said the FDA is asking for data from more patients—results that must come from a larger study that’s underway but won’t report data until later this year.

Investor and strategic partner mindsets have shifted toward optimal ways to protect their intellectual property (IP)  requirements, especially given evolving laws and social concerns.

Point32Health will now be able offer members access to LGBTQ+ Health, Included Health’s navigation and advocacy program for LGBTQ+ members. These members will have access to a care team led by LGBTQ+ care coordinators, who can help them find in-network, gender-affirming providers. They can also be connected to support groups and receive education on medical and legal issues. 

Colder weather will always pose an additional risk to people with COPD, but this COPD season does not need to be so detrimental. To turn the tide, payers and providers must invest in preventive care to meet patients where they are before their conditions deteriorate.

Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.

Check out news from BioMEMS Diagnostics, Rx Redefined, Ferrum Health and Avanlee Care.

For patients that are uninsured or not using their insurance and choosing to pay out of pocket, providers are required to give a patient an estimate of all reasonably expected costs ahead of time, referred to as the Good Faith Estimate (GFE).

Health plans today must consider what they want out of their pharmacy benefits and how to achieve something better for their members. And when they look at new platforms and processes that provide greater transparency, improved member experience, and simplicity in establishing and maintaining the technology, they’re likely to find that they don’t have to do things the way they always have.

Johnson & Johnson is stopping clinical development of an experimental HIV vaccine after the four-shot regimen did not beat a placebo in a late-stage study. The clinical trial failure comes follows the 2021 failure of the vaccine candidate in a different study population.